SOPHIA ANTIPOLIS, France – July 11, 2025 │ The latest update from KnowMade’s Therapeutic mRNA patent monitor highlights a dynamic second quarter in 2025 with notable expansion in both patent publications and grants.
Record-Breaking 272 Publications in Q2 as Top Rankings Shift
In Q2 2025, a total of 272 new scientific and patent publications were recorded in the therapeutic RNA field. The University of Texas leads this quarter with 17 new publications, all dedicated to therapeutic RNA delivery. BioNTech follows with 13 new publications focused primarily on delivery-related technologies. The Massachusetts Institute of Technology (MIT) secures the third position with 9 new publications covering a broader range of topics. These results underscore the influence of academic institutions in advancing mRNA innovation.
Figure 1: Q2 2025 Patent Filings by Key mRNA Therapeutics Innovators
Despite the increase in publication volume—from 257 in Q1 to 272 in Q2—the composition of leading contributors has notably shifted. BioNTech, which held the top spot in Q1 2025, has now dropped to second place. More strikingly, Sanofi, the University of Pennsylvania, and Moderna, all prominent in Q1, no longer appear in the top three for Q2. This evolution signals a rebalancing in the competitive landscape, with academic research institutions gaining momentum in therapeutic RNA innovation.
Newcomer to Watch: Amplitude Therapeutics
Amplitude Therapeutics is a Boston-based biotech company pioneering innovations in trans-amplifying RNA (taRNA) technologies for next-generation RNA therapeutics. Founded in 2022 the company focuses on a modular taRNA approach that separates the replicase and antigen components into distinct RNA molecules—an advancement that enhances delivery efficiency, dose flexibility, and manufacturing scalability. Backed by notable funding from CEPI and the Gates Foundation, Amplitude Therapeutics is positioned as a key innovator tackling global health challenges through RNA-based platforms.
The company’s recent intellectual property activity, including two international patent applications published in Q2 2025, highlights a two-component taRNA vaccine design leveraging lipid nanoparticles and chemically optimized RNA constructs. These developments mark a shift in the mRNA field toward more adaptable and efficient therapeutic formats. For a full analysis of Amplitude’s taRNA platform and IP filings, read our dedicated insight here.
Q2 2025: New Patent Grants Decline Slightly from Q1 Surge
The second quarter of 2025 saw 43 new granted patents across major jurisdictions (US, EP, JP, KR), marking a decrease from the 64 grants recorded in Q1 2025. This reduction follows a record-breaking start to the year but still reflects strong innovation output in therapeutic mRNA. The distribution of these newly granted rights continues to emphasize global engagement in RNA technologies. Notably, seven organizations—BioNTech, Moderna, Orna, Progeneer, Rinuagen, RNAimmune, and Sanofi—each secured multiple grants, highlighting their strategic efforts to fortify their IP portfolios. While Q2 did not match the peak observed in Q1, the sustained level of grant activity indicates continued progress in maturing research into enforceable IP assets.
Why Choose KnowMade’s Patent Monitor for mRNA Therapeutics
Staying ahead in the fast-moving field of mRNA therapeutics requires strategic insight into patent activity and innovation trends. KnowMade’s patent monitoring services provide timely, curated intelligence that helps companies track emerging IP, evaluate competitors, and uncover new R&D and partnership opportunities. By monitoring key patent filings and technological advances, organizations can strengthen their IP strategy, mitigate risks, and drive innovation with confidence. Empower your business with actionable data to navigate the evolving RNA therapeutics landscape and secure long-term competitive advantage. For more detailed insights into these developments and how they may impact your business, please contact us.
Press contact
contact@knowmade.fr
Le Drakkar, 2405 route des Dolines, 06560 Valbonne Sophia Antipolis, France
www.knowmade.com
About KnowMade
KnowMade is a Technology Intelligence and IP Strategy consulting company specialized in analysis of patents and scientific information. The company helps innovative companies and R&D organizations to understand their competitive landscape, follow technology trends, and find out opportunities and threats in terms of technology and patents.
KnowMade’s analysts combine their strong technology expertise and in-depth knowledge of patents with powerful analytics tools and methodologies to turn patents and scientific information into business-oriented report for decision makers working in R&D, Innovation Strategy, Intellectual Property, and Marketing. Our experts provide prior art search, patent landscape analysis, scientific literature analysis, patent valuation, IP due diligence and freedom-to-operate analysis. In parallel the company proposes litigation/licensing support, technology scouting and IP/technology watch service.
KnowMade has a solid expertise in Compound Semiconductors, Power Electronics, Batteries, RF Technologies & Wireless Communications, Solid-State Lighting & Display, Photonics, Memories, MEMS & Solid-State Sensors/Actuators, Semiconductor Manufacturing, Packaging & Assembly, Medical Devices, Medical Imaging, Microfluidics, Biotechnology, Pharmaceutics, and Agri-Food.